Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of age facing highly gonadotoxic treatment. Twenty years of experience at a single center.


Journal

Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343

Informations de publication

Date de publication:
05 2019
Historique:
received: 19 12 2018
accepted: 23 03 2019
pubmed: 29 3 2019
medline: 29 1 2020
entrez: 29 3 2019
Statut: ppublish

Résumé

The preservation of fertility is an integral part of care of children requiring gonadotoxic treatments for cancer or non-malignant diseases. In France, the cryopreservation of ovarian tissue has been considered and has been offered as a clinical treatment since its inception. The aim of this study is to review 20 years of activity in fertility preservation by ovarian tissue cryopreservation (OTC) for children and the feasibility of oocyte isolation and cryopreservation from the ovarian tissue at a single center. Retrospective study including patients aged 15 years or younger who underwent OTC, combined for some with oocyte cryopreservation of isolated oocytes, before a highly gonadotoxic treatment for malignant or non-malignant disease was initiated. We describe the evolution of activities in our program for fertility preservation and patient characteristics at the time of OTC and follow up. From April 1998 to December 2018, 418 girls and adolescents younger than 15 years of age underwent OTC, representing 40.5% of all females who have had ovarian tissue cryopreserved at our center. In all, 313 patients had malignant diseases and 105 had benign conditions. Between November 2009 and July 2013, oocytes were isolated and also cryopreserved in 50 cases. The mean age of patients was 6.9 years (range 0.3-15). The most frequent diagnoses in this cohort included neuroblastoma, acute leukemia and hemoglobinopathies; neuroblastoma being the most common diagnosis in very young patients. During follow up, three patients requested the use of their cryopreserved ovarian tissue. All had undergone ovarian tissue transplantation, one for puberty induction and the two others for restoring fertility. So far, no pregnancies have been achieved. Eighty-four patients who had OTC died. Ovarian tissue cryopreservation is the only available technique for preserving fertility of girls. To our knowledge this is the largest series of girls and adolescents younger than 15 years so far reported on procedures of OTC before highly gonadotoxic treatment in a single center.

Identifiants

pubmed: 30919447
doi: 10.1111/aogs.13616
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

630-637

Informations de copyright

© 2019 Nordic Federation of Societies of Obstetrics and Gynecology.

Auteurs

Catherine Poirot (C)

AYA Unit, Department of Hematology, Fertility Preservation, Hôpital Saint Louis, Paris, France.
Sorbonne University, Paris, France.

Laurence Brugieres (L)

Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.

Karima Yakouben (K)

Department of Pediatric Hemato-Immunology, Hospital Robert Debré, Paris, France.

Marie Prades-Borio (M)

Department of Reproductive Biology, Hospital Tenon, Paris, France.

Flora Marzouk (F)

Department of Reproductive Biology, Hospital Delafontaine, St Denis, France.

Guenolee de Lambert (G)

Department of Pediatric Surgery, Hospital Bicêtre, Le Kremlin-Bicêtre, France.

Helene Pacquement (H)

Department of Pediatric Oncology, Institut Curie, Paris, France.

Francoise Bernaudin (F)

Department of Pediatric Hematology, Center Hospitalier Intercommunal de Créteil, Créteil, France.

Benedicte Neven (B)

Department of Pediatric Hemato-Immunology, Hospital Necker, Paris, France.
Paris-Descartes University, Paris, France.

Annabel Paye-Jaouen (A)

Department of Pediatric Surgery, Hospital Robert Debré, Paris, France.

Corinne Pondarre (C)

Department of Pediatric Hematology, Center Hospitalier Intercommunal de Créteil, Créteil, France.

Nathalie Dhedin (N)

AYA Unit, Department of Hematology, Fertility Preservation, Hôpital Saint Louis, Paris, France.

Veronique Drouineaud (V)

Department of Reproductive Biology, Hospital Cochin, Paris, France.

Celine Chalas (C)

Department of Reproductive Biology, Hospital Cochin, Paris, France.

Helene Martelli (H)

Department of Pediatric Surgery, Hospital Bicêtre, Le Kremlin-Bicêtre, France.
Paris-Sud University, Le Kremlin Bicêtre, France.

Jean Michon (J)

Department of Pediatric Oncology, Institut Curie, Paris, France.

Veronique Minard (V)

Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.

Harry Lezeau (H)

Department of Pediatric Hematology, Center Hospitalier Intercommunal de Créteil, Créteil, France.

Francois Doz (F)

Department of Pediatric Oncology, Institut Curie, Paris, France.

Sabine Sarnacki (S)

Paris-Descartes University, Paris, France.
Department of Pediatric Surgery, Hospital Necker, Paris, France.

Pascale Philippe-Chomette (P)

Department of Pediatric Surgery, Hospital Robert Debré, Paris, France.

Christelle Dufour (C)

Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.

Valerie Laurence (V)

Department of Pediatric Oncology, Institut Curie, Paris, France.

Andre Baruchel (A)

Department of Pediatric Hemato-Immunology, Hospital Robert Debré, Paris, France.
Paris-Diderot University, Paris, France.

Jean-Philippe Wolf (JP)

Paris-Descartes University, Paris, France.
Department of Reproductive Biology, Hospital Cochin, Paris, France.

Nicolas Boissel (N)

AYA Unit, Department of Hematology, Fertility Preservation, Hôpital Saint Louis, Paris, France.
Paris-Diderot University, Paris, France.

Dominique Valteau-Couanet (D)

Department of Pediatric Oncology, Gustave Roussy Institute, Villejuif, France.

Jean-Hugues Dalle (JH)

Department of Pediatric Hemato-Immunology, Hospital Robert Debré, Paris, France.
Paris-Diderot University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH